Current status of hematopoietic cell transplantation for adult patients with hematologic diseases and solid tumors in Japan

Masahiro Imamura, Shigetaka Asano, Mine Harada, Yasuo Ikeda, Koji Kato, Shunichi Kato, Keisei Kawa, Seiji Kojima, Yasuo Morishima, Yoshihisa Morishita, Tatsutoshi Nakahata, Jun Okamura, Shinichiro Okamoto, Shintaro Shiobara, Mitsune Tanimoto, Masahiro Tsuchida, Yoshiko Atsuta, Kazuhito Yamamoto, Junji Tanaka, Nobuyuki Hamajima & 1 others Yoshihisa Kodera

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

A nationwide survey of hematopoietic cell transplantation (HCT) was started in Japan in 1991, and the analyzed survey data have been presented as the annual report of the Japan Society for Hematopoietic Cell Transplantation. The 10-year overall survival (OS) rates after HCT for each disease are as follows: acute myelogenous leukemia, 44.2%; acute lymphocytic leukemia, 33.7%; adult T-cell leukemia, 24.6%; chronic myelogenous leukemia, 53.3%; myelodysplastic syndrome, 37.3%; non-Hodgkin's lymphoma, 41.5%; Hodgkin's lymphoma, 50.8%; aplastic anemia, 72.5%; breast cancer, 37.1%; germ cell tumor, 52.6%; and ovarian cancer, 44.2%.The 5-year OS rates for multiple myeloma and lung cancer were 40.6% and 23.6%, respectively. Except in cord blood transplantation, engraftment was accomplished in more than 90% of patients. The respective frequencies of acute graft-versus-host disease (GVHD) and chronic GVHD were 41.1% and 34.9% for related bone marrow transplantation (BMT), 66.8% and 34.5% for unrelated BMT, 52.9% and 36.0% for allogeneic peripheral blood stem cell transplantation, and 53.3% and 32.1% for allogeneic cord blood transplantation. OS for each disease was analyzed by patient age, stem cell source, donor type, disease status, and disease type. These data provide objective and valuable information for hematologists as well as for patients who need HCT.

Original languageEnglish
Pages (from-to)164-178
Number of pages15
JournalInternational Journal of Hematology
Volume83
Issue number2
DOIs
Publication statusPublished - Feb 2006

Fingerprint

Hematologic Diseases
Cell Transplantation
Japan
Graft vs Host Disease
Bone Marrow Transplantation
Fetal Blood
Neoplasms
Survival Rate
Transplantation
Peripheral Blood Stem Cell Transplantation
Adult T Cell Leukemia Lymphoma
Annual Reports
Aplastic Anemia
Germ Cell and Embryonal Neoplasms
Myelodysplastic Syndromes
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Multiple Myeloma
Hodgkin Disease
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia

Keywords

  • Graft-versus-host disease
  • Hematologic malignancies
  • Hematopoietic cell transplantation
  • Overall survival
  • Solid tumors

ASJC Scopus subject areas

  • Hematology

Cite this

Current status of hematopoietic cell transplantation for adult patients with hematologic diseases and solid tumors in Japan. / Imamura, Masahiro; Asano, Shigetaka; Harada, Mine; Ikeda, Yasuo; Kato, Koji; Kato, Shunichi; Kawa, Keisei; Kojima, Seiji; Morishima, Yasuo; Morishita, Yoshihisa; Nakahata, Tatsutoshi; Okamura, Jun; Okamoto, Shinichiro; Shiobara, Shintaro; Tanimoto, Mitsune; Tsuchida, Masahiro; Atsuta, Yoshiko; Yamamoto, Kazuhito; Tanaka, Junji; Hamajima, Nobuyuki; Kodera, Yoshihisa.

In: International Journal of Hematology, Vol. 83, No. 2, 02.2006, p. 164-178.

Research output: Contribution to journalArticle

Imamura, M, Asano, S, Harada, M, Ikeda, Y, Kato, K, Kato, S, Kawa, K, Kojima, S, Morishima, Y, Morishita, Y, Nakahata, T, Okamura, J, Okamoto, S, Shiobara, S, Tanimoto, M, Tsuchida, M, Atsuta, Y, Yamamoto, K, Tanaka, J, Hamajima, N & Kodera, Y 2006, 'Current status of hematopoietic cell transplantation for adult patients with hematologic diseases and solid tumors in Japan', International Journal of Hematology, vol. 83, no. 2, pp. 164-178. https://doi.org/10.1532/IJH97.05134
Imamura, Masahiro ; Asano, Shigetaka ; Harada, Mine ; Ikeda, Yasuo ; Kato, Koji ; Kato, Shunichi ; Kawa, Keisei ; Kojima, Seiji ; Morishima, Yasuo ; Morishita, Yoshihisa ; Nakahata, Tatsutoshi ; Okamura, Jun ; Okamoto, Shinichiro ; Shiobara, Shintaro ; Tanimoto, Mitsune ; Tsuchida, Masahiro ; Atsuta, Yoshiko ; Yamamoto, Kazuhito ; Tanaka, Junji ; Hamajima, Nobuyuki ; Kodera, Yoshihisa. / Current status of hematopoietic cell transplantation for adult patients with hematologic diseases and solid tumors in Japan. In: International Journal of Hematology. 2006 ; Vol. 83, No. 2. pp. 164-178.
@article{784ceedd5e944d8bb1479a47626d3295,
title = "Current status of hematopoietic cell transplantation for adult patients with hematologic diseases and solid tumors in Japan",
abstract = "A nationwide survey of hematopoietic cell transplantation (HCT) was started in Japan in 1991, and the analyzed survey data have been presented as the annual report of the Japan Society for Hematopoietic Cell Transplantation. The 10-year overall survival (OS) rates after HCT for each disease are as follows: acute myelogenous leukemia, 44.2{\%}; acute lymphocytic leukemia, 33.7{\%}; adult T-cell leukemia, 24.6{\%}; chronic myelogenous leukemia, 53.3{\%}; myelodysplastic syndrome, 37.3{\%}; non-Hodgkin's lymphoma, 41.5{\%}; Hodgkin's lymphoma, 50.8{\%}; aplastic anemia, 72.5{\%}; breast cancer, 37.1{\%}; germ cell tumor, 52.6{\%}; and ovarian cancer, 44.2{\%}.The 5-year OS rates for multiple myeloma and lung cancer were 40.6{\%} and 23.6{\%}, respectively. Except in cord blood transplantation, engraftment was accomplished in more than 90{\%} of patients. The respective frequencies of acute graft-versus-host disease (GVHD) and chronic GVHD were 41.1{\%} and 34.9{\%} for related bone marrow transplantation (BMT), 66.8{\%} and 34.5{\%} for unrelated BMT, 52.9{\%} and 36.0{\%} for allogeneic peripheral blood stem cell transplantation, and 53.3{\%} and 32.1{\%} for allogeneic cord blood transplantation. OS for each disease was analyzed by patient age, stem cell source, donor type, disease status, and disease type. These data provide objective and valuable information for hematologists as well as for patients who need HCT.",
keywords = "Graft-versus-host disease, Hematologic malignancies, Hematopoietic cell transplantation, Overall survival, Solid tumors",
author = "Masahiro Imamura and Shigetaka Asano and Mine Harada and Yasuo Ikeda and Koji Kato and Shunichi Kato and Keisei Kawa and Seiji Kojima and Yasuo Morishima and Yoshihisa Morishita and Tatsutoshi Nakahata and Jun Okamura and Shinichiro Okamoto and Shintaro Shiobara and Mitsune Tanimoto and Masahiro Tsuchida and Yoshiko Atsuta and Kazuhito Yamamoto and Junji Tanaka and Nobuyuki Hamajima and Yoshihisa Kodera",
year = "2006",
month = "2",
doi = "10.1532/IJH97.05134",
language = "English",
volume = "83",
pages = "164--178",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Current status of hematopoietic cell transplantation for adult patients with hematologic diseases and solid tumors in Japan

AU - Imamura, Masahiro

AU - Asano, Shigetaka

AU - Harada, Mine

AU - Ikeda, Yasuo

AU - Kato, Koji

AU - Kato, Shunichi

AU - Kawa, Keisei

AU - Kojima, Seiji

AU - Morishima, Yasuo

AU - Morishita, Yoshihisa

AU - Nakahata, Tatsutoshi

AU - Okamura, Jun

AU - Okamoto, Shinichiro

AU - Shiobara, Shintaro

AU - Tanimoto, Mitsune

AU - Tsuchida, Masahiro

AU - Atsuta, Yoshiko

AU - Yamamoto, Kazuhito

AU - Tanaka, Junji

AU - Hamajima, Nobuyuki

AU - Kodera, Yoshihisa

PY - 2006/2

Y1 - 2006/2

N2 - A nationwide survey of hematopoietic cell transplantation (HCT) was started in Japan in 1991, and the analyzed survey data have been presented as the annual report of the Japan Society for Hematopoietic Cell Transplantation. The 10-year overall survival (OS) rates after HCT for each disease are as follows: acute myelogenous leukemia, 44.2%; acute lymphocytic leukemia, 33.7%; adult T-cell leukemia, 24.6%; chronic myelogenous leukemia, 53.3%; myelodysplastic syndrome, 37.3%; non-Hodgkin's lymphoma, 41.5%; Hodgkin's lymphoma, 50.8%; aplastic anemia, 72.5%; breast cancer, 37.1%; germ cell tumor, 52.6%; and ovarian cancer, 44.2%.The 5-year OS rates for multiple myeloma and lung cancer were 40.6% and 23.6%, respectively. Except in cord blood transplantation, engraftment was accomplished in more than 90% of patients. The respective frequencies of acute graft-versus-host disease (GVHD) and chronic GVHD were 41.1% and 34.9% for related bone marrow transplantation (BMT), 66.8% and 34.5% for unrelated BMT, 52.9% and 36.0% for allogeneic peripheral blood stem cell transplantation, and 53.3% and 32.1% for allogeneic cord blood transplantation. OS for each disease was analyzed by patient age, stem cell source, donor type, disease status, and disease type. These data provide objective and valuable information for hematologists as well as for patients who need HCT.

AB - A nationwide survey of hematopoietic cell transplantation (HCT) was started in Japan in 1991, and the analyzed survey data have been presented as the annual report of the Japan Society for Hematopoietic Cell Transplantation. The 10-year overall survival (OS) rates after HCT for each disease are as follows: acute myelogenous leukemia, 44.2%; acute lymphocytic leukemia, 33.7%; adult T-cell leukemia, 24.6%; chronic myelogenous leukemia, 53.3%; myelodysplastic syndrome, 37.3%; non-Hodgkin's lymphoma, 41.5%; Hodgkin's lymphoma, 50.8%; aplastic anemia, 72.5%; breast cancer, 37.1%; germ cell tumor, 52.6%; and ovarian cancer, 44.2%.The 5-year OS rates for multiple myeloma and lung cancer were 40.6% and 23.6%, respectively. Except in cord blood transplantation, engraftment was accomplished in more than 90% of patients. The respective frequencies of acute graft-versus-host disease (GVHD) and chronic GVHD were 41.1% and 34.9% for related bone marrow transplantation (BMT), 66.8% and 34.5% for unrelated BMT, 52.9% and 36.0% for allogeneic peripheral blood stem cell transplantation, and 53.3% and 32.1% for allogeneic cord blood transplantation. OS for each disease was analyzed by patient age, stem cell source, donor type, disease status, and disease type. These data provide objective and valuable information for hematologists as well as for patients who need HCT.

KW - Graft-versus-host disease

KW - Hematologic malignancies

KW - Hematopoietic cell transplantation

KW - Overall survival

KW - Solid tumors

UR - http://www.scopus.com/inward/record.url?scp=33646823333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646823333&partnerID=8YFLogxK

U2 - 10.1532/IJH97.05134

DO - 10.1532/IJH97.05134

M3 - Article

VL - 83

SP - 164

EP - 178

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 2

ER -